MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

[1]  Len Taing,et al.  CoBRA: Containerized Bioinformatics workflow for Reproducible ChIP/ATAC-seq Analysis - from differential peak calling to pathway analysis , 2020, bioRxiv.

[2]  M. Rubin,et al.  A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance , 2020, Nature Cancer.

[3]  Henry W. Long,et al.  Prostate cancer reactivates developmental epigenomic programs during metastatic progression , 2020, Nature Genetics.

[4]  Simran K. Sandhu,et al.  Urethral luminal epithelia are castration‐insensitive cells of the proximal prostate , 2020, The Prostate.

[5]  D. Pe’er,et al.  Regenerative potential of prostate luminal cells revealed by single-cell analysis , 2020, Science.

[6]  F. Jamali,et al.  Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[7]  Yuan Wang,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Metastatic Brain Tumor Microenvironment of Non Small Cell Lung Cancer , 2019, bioRxiv.

[8]  Mihai I Truica,et al.  Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. , 2019, Cancer cell.

[9]  P. Nelson,et al.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.

[10]  Jacob D. Jaffe,et al.  High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program , 2019, Nature Communications.

[11]  A. Chinnaiyan,et al.  Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer , 2019, Clinical Cancer Research.

[12]  D. Strand,et al.  Expansion of Luminal Progenitor Cells in the Aging Mouse and Human Prostate , 2019, Cell reports.

[13]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[14]  R. Vessella,et al.  A Positive Role of c-Myc in Regulating Androgen Receptor and its Splice Variants in Prostate Cancer , 2019, Oncogene.

[15]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[16]  Dharmesh D. Bhuva,et al.  Single sample scoring of molecular phenotypes , 2018, BMC Bioinformatics.

[17]  Myles A Brown,et al.  Transcriptional Regulation in Prostate Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[18]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[19]  Jonathan Scolnick,et al.  Faculty Opinions recommendation of Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[20]  K. D. Sørensen,et al.  Germline variation at 8q24 and prostate cancer risk in men of European ancestry , 2018, Nature Communications.

[21]  A. Shilatifard,et al.  Born to run: control of transcription elongation by RNA polymerase II , 2018, Nature Reviews Molecular Cell Biology.

[22]  Bo Li,et al.  VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis , 2018, BMC Bioinformatics.

[23]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[24]  Jun Luo,et al.  Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression. , 2017, European urology.

[25]  P. Stopka,et al.  On the tear proteome of the house mouse (Mus musculus musculus) in relation to chemical signalling , 2017, PeerJ.

[26]  Bernat Gel,et al.  karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data , 2017, bioRxiv.

[27]  Stefan J. Barfeld,et al.  c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks , 2017, EBioMedicine.

[28]  B. Trock,et al.  Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Nelson,et al.  LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.

[30]  Kaitlyn M. Gayvert,et al.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.

[31]  Tao Liu,et al.  ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline , 2016, BMC Bioinformatics.

[32]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[33]  Susanne Mandrup,et al.  Cofactor squelching: Artifact or fact? , 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.

[34]  Kati Räsänen,et al.  Emerging Roles of SPINK1 in Cancer. , 2016, Clinical chemistry.

[35]  J. Shendure,et al.  Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.

[36]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[37]  Hamid Bolouri,et al.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer , 2016 .

[38]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[39]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[40]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[41]  Henry W. Long,et al.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.

[42]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[43]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[44]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[45]  S. Hautaniemi,et al.  Tissue‐specific pioneer factors associate with androgen receptor cistromes and transcription programs , 2014, The EMBO journal.

[46]  Hanfei Sun,et al.  Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.

[47]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[48]  C. Dang.  MYC, metabolism, cell growth, and tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.

[49]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[50]  X. Liu,et al.  Amplitude Modulation of Androgen Signaling by C-myc Material Supplemental , 2013 .

[51]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[52]  Stephen R. Piccolo,et al.  A single-sample microarray normalization method to facilitate personalized-medicine workflows. , 2012, Genomics.

[53]  E. Klein,et al.  High-Grade Prostatic Intraepithelial Neoplasia , 2012, Korean journal of urology.

[54]  Timothy J. Durham,et al.  Systematic analysis of chromatin state dynamics in nine human cell types , 2011, Nature.

[55]  Matthew L. Freedman,et al.  Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis , 2010, PLoS genetics.

[56]  M. Nóbrega,et al.  An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. , 2010, Genome research.

[57]  W. Gerald,et al.  Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3 , 2010, Prostate Cancer and Prostatic Diseases.

[58]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[59]  R. Matusik,et al.  Characterization of cis elements of the probasin promoter necessary for prostate‐specific gene expression , 2010, The Prostate.

[60]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[61]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[62]  Cole Trapnell,et al.  Role of Rodent Secondary Motor Cortex in Value-based Action Selection Nih Public Access Author Manuscript , 2006 .

[63]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[64]  Christopher B. Burge,et al.  c-Myc Regulates Transcriptional Pause Release , 2010, Cell.

[65]  P. Pandolfi,et al.  Prostate Cancer Progression , 2010 .

[66]  Christopher A. Haiman,et al.  The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer , 2009, Nature Genetics.

[67]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[68]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[69]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[70]  M. Gross,et al.  Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  D. Bostwick,et al.  High-grade prostatic intraepithelial neoplasia. , 2004, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[73]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[74]  C. Bieberich,et al.  Ventral prostate predominant l, a novel mouse gene expressed exclusively in the prostate * , 2002, The Prostate.

[75]  R. Matusik,et al.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.

[76]  F. Alt,et al.  N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. , 2000, Genes & development.

[77]  M. Pagano,et al.  Survival analysis. , 1996, Nutrition.

[78]  Berthold Lausen,et al.  Maximally selected rank statistics , 1992 .

[79]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[80]  A. W. Harris,et al.  The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells , 1988, The Journal of experimental medicine.

[81]  S. Liao,et al.  Androgen-sensitive spermine-binding protein of rat ventral prostate. Purification of the protein and characterization of the hormonal effect. , 1979, The Biochemical journal.

[82]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[83]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[84]  J. W. White.  II. The Present Position of the Surgery of the Hypertrophied Prostate. , 1904, Annals of surgery.

[85]  White Jw.  I. The Results of Double Castration in Hypertrophy of the Prostate. , 1895 .

[86]  J. W. White.  II. The Present Position of the Surgery of the Hypertrophied Prostate. , 1893, Annals of surgery.